Clearmind Medicine Inc. (CMND) News
Track canonical SquawkNews coverage tagged to CMND, Clearmind Medicine Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 23 indexed stories across 17 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
NeuroThera Highlights Enhancement of U.S. Patent Portfolio Through Collaboration with Clearmind Covering LSD, Ketamine and Ibogaine Combinations
(TheNewswire)The U.S. patent applications cover proprietary combinations of NeuroThera’s PEA technology with LSD, ketamine and ibogaine for potential therapeutic applications, including mental health disorders, such as d
NEWS | Sep 23, 2026, 12:16 PM UTC
L
Clearmind Enhances U.S. IP Presence with Publication of Three Patent Applications Covering LSD, Ketamine and Ibogaine Combinations
The covered applications address potential therapeutic uses across a range of indications, including mental health disorders, such as depression and PTSD as well as substance use disordersVancouver, Canada, Sept. 23, 202
NEWS | Sep 23, 2026, 12:01 PM UTC
L
CMND - Clearmind Enhances U.S. IP Presence with Publication of Three Patent Applications Covering LSD, Ketamine and Ibogaine Combinations
CMND - Clearmind Enhances U.S. IP Presence with Publication of Three Patent Applications Covering LSD, Ketamine and Ibogaine Combinations
NEWS | Sep 23, 2026, 11:57 AM UTC
L
CMND - Clearmind Medicine Delivers Briefing to FDA Following Invitation to Historic Psychedelic Hearing in Washington, D.C.
CMND - Clearmind Medicine Delivers Briefing to FDA Following Invitation to Historic Psychedelic Hearing in Washington, D.C.
REGULATION | Sep 17, 2026, 11:42 AM UTC
M
CMND gets Yale IRB approval for CMND-100 Phase I/II Parts B and C recruitment
Clearmind Medicine received Yale IRB approval, enabling patient recruitment for Parts B and C of its CMND-100 Phase I/II trial following positive safety results.
EQUITY | Sep 08, 2026, 11:42 AM UTC
M
CMND slips after Clearmind agrees to buy 51% EV charging stake
Clearmind Medicine shares fell in Friday premarket after it agreed to acquire a 51% controlling stake in Charging Robotics for $2.5 million, plus a $1.5 million loan at 4% interest, expected to close the week of Sept. 7.
MNA | Sep 04, 2026, 12:59 PM UTC
M
CMND signs deal to acquire 51% stake in wireless charging company
Clearmind Medicine signed a definitive agreement to acquire a 51% stake in a wireless charging company for automated parking and robotaxis.
MNA | Sep 04, 2026, 11:32 AM UTC
L
Clearmind reaches milestone; CMND-100 Phase IIa for alcohol use disorder underway
Clearmind says CMND-100 Phase IIa is underway for an alcohol use disorder trial, with one-third of Part C enrolled.
EQUITY | Sep 01, 2026, 11:37 AM UTC
L
SciSparc unit and Clearmind publish U.S. patent application for MDMA-PEA use
SciSparc subsidiary NeuroThera Labs and Clearmind Medicine say the USPTO published a U.S. patent application covering MDMA and N-acylethanolamines, including PEA, for methods of treating PTSD, anxiety and eating disorder
REGULATION | Aug 24, 2026, 12:54 PM UTC
L
CMND - Clearmind Advances MDMA-N-acylethanolamines IP for the Treatment of PTSD Amid Rising U.S. Federal Support for Psychedelic Innovation
CMND - Clearmind Advances MDMA-N-acylethanolamines IP for the Treatment of PTSD Amid Rising U.S. Federal Support for Psychedelic Innovation
EQUITY | Aug 24, 2026, 12:03 PM UTC
M
Clearmind advances CMND-100 after primary safety endpoint
Clearmind says CMND advances CMND-100 to alcohol use disorder patients after achieving its primary safety endpoint.
EQUITY | Aug 13, 2026, 11:36 AM UTC
H
Clearmind Reaches Clinical Trial Milestone
Clearmind clears clinical trial progression
EQUITY | Aug 06, 2026, 12:02 PM UTC
L
CMND - Clearmind Medicine Signs Letter of Intent to Acquire 51% Majority Stake in EV Wireless Charging Solutions for Automated Parking Syste
CMND - Clearmind Medicine Signs Letter of Intent to Acquire 51% Majority Stake in EV Wireless Charging Solutions for Automated Parking Systems Company
MNA | Aug 03, 2026, 12:02 PM UTC
L
CMND - Clearmind Announces Positive Safety Findings for CMND 100, Demonstrating Consistent Tolerability Throughout Full Dose Escalation in P
CMND - Clearmind Announces Positive Safety Findings for CMND 100, Demonstrating Consistent Tolerability Throughout Full Dose Escalation in Part A of its FDA -Regulated Clinical Trial
REGULATION | Jul 30, 2026, 12:32 PM UTC
L
CMND Clearmind Medicine Inc., a clinical-stage Biotechnology company pioneering nonhallucinogenic neuroplastogen-derived treatments for Alco
CMND Clearmind Medicine Inc., a clinical-stage Biotechnology company pioneering nonhallucinogenic neuroplastogen-derived treatments for Alcohol Use Disorder ("AUD"), addiction, and weight management, recently announced t
EQUITY | Jul 28, 2026, 11:53 AM UTC
L
CMND Clearmind Medicine - files Hong Kong patent application for psychedelic compounds targeting ptsd
CMND Clearmind Medicine - files Hong Kong patent application for psychedelic compounds targeting ptsd
EQUITY | Jul 20, 2026, 11:55 AM UTC
L
CMND Clearmind Medicine - results validate Clearmind nasal drug-delivery platform for meai
CMND Clearmind Medicine - results validate Clearmind nasal drug-delivery platform for meai
EQUITY | Jul 16, 2026, 01:30 PM UTC
L
CMND Clearmind Medicine reports positive retention results for intranasal formulation of its psychedelic-based neuroplastogen meai
CMND Clearmind Medicine reports positive retention results for intranasal formulation of its psychedelic-based neuroplastogen meai
EQUITY | Jul 16, 2026, 01:30 PM UTC
H
FDA announces availability of final guidance for psychedelic drug research
The agency said,...
EARNINGS | Jul 15, 2026, 03:12 PM UTC
L
Clearmind Medicine submits response to HHS request for information
Clearmind Medicine announced that it has submitted a formal response to the U.S. Department of Health and Human Services, or HHS, request for information about MEAI's potential as an innovative, empirically-evidenced int
EQUITY | Jul 10, 2026, 12:36 PM UTC
L
Psychedelic: Compass Pathways reports six-month data for psilocybin drug
In this week's "Psychedelic," recurring series focused on psychedelic stock news, looks back on study results, drug delivery evaluation and last patient dosing. COMPASS PATHWAYS REPORTS SIX-MONTH DATA FROM COMP006 TRIAL:
EQUITY | Jul 09, 2026, 01:49 PM UTC
M
CMND Completes Trial
Clearmind Medicine completes treatment for all participants in Part A of ongoing Phase I/II clinical trial evaluating CMND-100 for treatment of alcohol use disorder
EQUITY | Jun 22, 2026, 12:21 PM UTC
H
CMND Completes Phase I/II Trial
Clearmind Medicine completes Part A treatment in FDA-regulated Phase I/II trial
EQUITY | Jun 22, 2026, 12:07 PM UTC